- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lucio Gordan Outlines Challenges to Implementing a New OCM
"I am not convinced yet that the Oncology Care First Model truly takes into account necessary elements, including high-cost drugs," said Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists.
"I am not convinced yet that the Oncology Care First Model truly takes into account necessary elements, including high-cost drugs," said Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists.
Transcript:
In your opinion, does the proposed Oncology Care First Model go far enough to address concerns that the OCM did not adequately reimburse practices for high-cost therapies?
The Oncology Care First model remains very difficult to understand, in my opinion. I think Community Oncology Alliance and others have sent several initial suggestions and recommendations to CMS, CMMI (Capability Maturity Model Integration), as to how to design Oncology Care First. I am not convinced yet that Oncology Care First truly takes into account the necessary elements, including high-cost drugs. I think we lack understanding as far as the details, as to how this will be operationalized. We really have embraced the Oncology Care Model. We do think that value-based care should obviously continue in cancer care in the United States. It is just taking maybe too quick of a step from moving from the current Oncology Care Model to Oncology Care First. There are a lot of things that need to be understood and the details need to be ironed out for us to truly embrace this as a solution for us.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
